asx announcements

ASX Announcements Archive 2012

17 Dec 2012

Change of Director’s Interest Notice

read more >>
11 Dec 2012

Open Briefing interview with MD & CEO Robert Klupacs

read more >>
21 Nov 2012

Change of Director's Interest Notice

read more >>
21 Nov 2012

Appendix 3B

read more >>
20 Nov 2012

Results of Annual General Meeting 20 November 2012

read more >>
20 Nov 2012

CEO AGM Presentation to shareholders

read more >>
20 Nov 2012

Chairman's Address to Shareholders

read more >>
20 Nov 2012

CEO AGM Presentation to Shareholders

read more >>
15 Nov 2012

Circadian grants world-wide licence to Bio-Rad to market research products

read more >>
08 Nov 2012

VGX-100 Poster Presentation at EORTC

read more >>
08 Nov 2012

VGX-100 Poster Presentation at EORTC

read more >>
07 Nov 2012

VGX-100 Top 10 Oncology Candidate Windhover Conference

read more >>
02 Nov 2012

AusBiotech Presentation Company Update

read more >>
22 Oct 2012

Annual Report / Notice of AGM and Proxy

read more >>
02 Oct 2012

Dr Errol Malta – Resignation as Director

read more >>
24 Sep 2012

Open Briefing - FY2012 Results and Outlook

read more >>
24 Aug 2012

Appendix 3B

read more >>
24 Aug 2012

Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)

read more >>
23 Aug 2012

Preliminary Final Report (Appendix 4E) - Financial Year Ended 30 June 2012

read more >>
17 Jul 2012

Update to Substantial Holding Notice for Antisense Therapeutics Limited

read more >>
12 Jul 2012

Change of Director’s Interest Notice

read more >>
10 Jul 2012

Change of Director’s Interest Notice

read more >>
09 Jul 2012

Alpha Securities Analyst Investment Research Report Available on Circadian Website

read more >>
07 Jul 2012

Bio 2012 - Building a Diagnostics Franchise

read more >>
27 Jun 2012

Commercial Launch of CUP Test

read more >>
22 Jun 2012

Appendix 3B

read more >>
22 Jun 2012

Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)

read more >>
12 Jun 2012

Circadian makes $1M Share Placement

read more >>
12 Jun 2012

Reinstatement to Official Quotation

read more >>
07 Jun 2012

Suspension Confirm

read more >>
07 Jun 2012

Suspension Request

read more >>
05 Jun 2012

Request for Trading Halt

read more >>
01 Jun 2012

Updated Corporate Presentation

read more >>
16 May 2012

Appendix 3B

read more >>
27 Apr 2012

Notice of Ceasing to be a Substantial Holder

read more >>
02 Apr 2012

Change of Director’s Interest Notice

read more >>
29 Mar 2012

Update to Substantial Holding Notice for Antisense Therapeutics Limited

read more >>
15 Mar 2012

Analyst Investment Research Report Available on Circadian Website

read more >>
09 Mar 2012

Positive data published on performance of Circadian’s Cancers of Unknown Primary Diagnostic Test

read more >>
09 Mar 2012

Development of a Gene Expression Based Assay to Determine the Origin of Metastatic Carcinomas of Unknown Primary

read more >>
20 Feb 2012

Open Briefing with CEO & MD Robert Klupacs - Half Year Results and Outlook

read more >>
16 Feb 2012

Half-Year Financial Report & Operational Achievements

read more >>
30 Jan 2012

VGX-100 identified as potential new therapy for improving corneal graft survival

read more >>
12 Jan 2012

CEO Presentation at Biotech Showcase San Francisco

read more >>
09 Jan 2012

Circadian commences first Phase 1 clinical trial of VEGF-C antibody VGX-100 in cancer patients

read more >>